Using photopheresis to treat early-stage Mycosis Fungoides

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of photopheresis therapy to improve outcomes in patients with early-stage cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides. Traditionally, photopheresis has been reserved for late-stage CTCL, but recent findings suggest that early-stage patients may also exhibit markers indicating potential benefit from this treatment. The study will utilize the THERAKOS® CELLEX Photopheresis System in conjunction with UVADEX® to assess its efficacy in patients with specific staging and blood abnormalities. Participants will be closely monitored for clinical responses to the therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Who are male or female, over the age of 18 and \<40 kg body weight with adequate veins to provide intravenous access.
2. Who are willing to adhere to the protocol and sign an Informed Patient Consent Document
3. Must not be on any other investigational device/drug treatment.
4. Who have the diagnosis of Mycosis Fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotropic or folliculocentric T-cells) with appropriate staging as IA, IB or IIA: T1 or T2 (patches or plaques) with measurable lesions.
5. With IA stage must demonstrate a minor blood abnormality by morphology/laboratory assessment.
6. With IIA stage - clinically significant nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.
7. Must be willing and able to discontinue concomitant medications for MF. Subjects currently taking the following drugs must discontinue medication with the following wash out periods prior to enrollment in the trial: PUVA or UVB Therapy - 4 weeks, topical nitrogen mustard or other topical chemotherapy - 4 weeks, bexarotene capsules or other systemic biologic agent - 3 weeks washout, high dose topical steroids, topical retinoids or immunotherapy - 2 week washout with 1% topical hydrocortisone , oral steroids above 10 mg - 30 day washout, unless subject has Addison's Disease or adrenal insufficiency
8. Who are refractory to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, topical nitrogen mustard, Bexarotene, PUVA therapy, electron beam radiation, biological response modifiers or oral methotrexate.
9. Must be willing to abstain from therapeutic sunbathing, phototherapy, tanning beds, etc. for the duration of the study.

Exclusion Criteria:

1. Who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB - IVB
2. Who are unable to tolerate extracorporeal volume loss i.e., severe cardiac disease/anemia
3. With deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.
4. With lipemic plasma \>500 ng/dL, uncontrolled diabetes, history of liver damage (2.5 x normal alanine transaminase (ALT), aspartate aminotransferase (AST), porphyria, lupus, positive tests for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody or Hepatitis B Surface Antigen, severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen, and idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen compounds, heparin, or citrate.
5. On oral prednisone therapy or high potency topical steroids.
6. Who are pregnant or nursing a child.

Where it's running

• Columbia University Irving Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Larisa Geskin, MD — Columbia University
• Study coordinator: Larisa Geskin, MD
• Email: ljg2145@cumc.columbia.edu
• Phone: 212-305-5293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma

  This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting at 10 sites Phase 1 SciTech Development, Inc. · Scottsdale, Arizona and 9 other locations · NCT04234048

• Collection of blood, urine, and tissue samples for research on skin conditions

  This study is collecting blood, urine, and tissue samples from people with skin conditions like cutaneous T-cell lymphoma, eczema, and atopic dermatitis to help improve treatments in the future.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT00177268

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

• Ropeginterferon treatment for cutaneous T‑cell lymphoma

  This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.